Pilot study of immunization with recombinant canarypox virus vCP1469A expressing the MAGE-1.A1 and MAGE-3.A1 cytolytic T lymphocytes epitopes in patients with malignant melanoma, non-small cell lung carcinoma, head-and-neck squamous cell carcinoma, esopha

Long title

Pilot study of immunization with recombinant canarypox virus vCP1469A expressing the MAGE-1.A1 and MAGE-3.A1 cytolytic T lymphocytes epitopes in patients with malignant melanoma, non-small cell lung carcinoma, head-and-neck squamous cell carcinoma, esophageal squamous cell carcinoma or bladder carcinoma

Date receipt dossier

26 March, 1998

Company / Sponsor

Pasteur Mérieux Connaught

Phase

I

Treated organism

Humans

Indication category

Cancer therapy

Disease

Malignant melanoma, Non-Small Cell Lung Cancer, Squamous cell carcinoma of the Head and Neck, Bladder transitional cell carcinoma

Therapeutic approach

Immunotherapy

Genetic modification

HLA-A1 restricted CTL epitope of MAGE-1 and
MAGE-3 genes

Method of transfer of nucleic acid of interest

Canarypox Virus (ALVAC)

Administered biological material

Recombinant Canarypox Virus

Route of administration

Subcutaneous

Locations in Belgium

Cliniques Universitaires St-Luc, Brussels

Type of procedure

Contained use only

Current status

Authorized

Pharmaceutical study code

MEL01198